Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammed Akbani

Vascular Surgery Lima, OH Medical Doctor

NPI 1356675656 CMS profile 2791525

830 W High St Ste 207, Lima, OH 45801

Open in the dashboard

General payments

$15,752

213 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammed Akbani of Lima, OH is reported in the CMS Open Payments database as having received $15,752 across 213 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,938 27
2024 General $3,032 33
2023 General $1,531 20
2022 General $3,426 35
2021 General $1,615 30
2020 General $1,786 28
2019 General $2,424 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammed Akbani
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Mohammed Akbani were reported at $1,938. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Mohammed Akbani Vascular Surgery median Middle half National median
2019 $2,424 $796 $226–$2,363 $163
2020 $1,786 $348 $118–$1,110 $114
2021 $1,615 $471 $158–$1,421 $132
2022 $3,426 $725 $222–$2,183 $149
2023 $1,531 $836 $257–$2,440 $160
2024 $3,032 $909 $252–$2,619 $164
2025 $1,938 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inari Medical, Inc. $4,360 45 payments
  2. W. L. Gore & Associates, Inc. $4,037 36 payments
  3. Medtronic Vascular, Inc. $1,566 12 payments
  4. Stryker Corporation $1,015 12 payments
  5. Medtronic, Inc. $948 16 payments
  6. LeMaitre Vascular, Inc. $880 8 payments
  7. Centinel Spine, LLC $543 3 payments
  8. Cook Medical LLC $250 1 payment
  9. Janssen Pharmaceuticals, Inc $244 12 payments
  10. Bolton Medical Inc $215 4 payments
  11. Other $1,695 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,919 194 payments
  2. Travel and Lodging $4,545 17 payments
  3. Honoraria $250 1 payment
  4. Education $38 1 payment
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $5,275 53 payments
  2. CT THROMBECTOMY SYSTEM KIT $3,274 37 payments
  3. GORE EXCLUDER Iliac Branch Endoprosthesis $1,444 10 payments
  4. IN.PACT Admiral $1,408 7 payments
  5. TAG Thoracic Endoprosthesis $1,124 9 payments
  6. ARTEGRAFT VASCULAR GRAFT $635 5 payments
  7. GORE TAG Thoracic Endoprosthesis $614 5 payments
  8. PRODISC L $543 3 payments
  9. 1788 $517 4 payments
  10. HawkOne $300 6 payments
  11. Other $5,673 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

98

Median for Vascular Surgery: 122

Drug cost

$21,411

Median for Vascular Surgery: $14,135

Branded share of claims

73.5%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 27 $20,444
Pregabalin Generic 12 $458
Clopidogrel Clopidogrel Bisulfate Brand 26 $262
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 19 $137
Gabapentin Generic 14 $110

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 99 billing codes

Paid by Medicare

$95,868

Medicare's payments for the services billed

Medicare patients

664

Average age 74

Services billed

1,129

303 women, 361 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 52%
Diabetes 45%
Chronic kidney disease 45%
Heart failure 36%
COPD 33%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record